il-6 mediated dysfunction treatment method, rheumatoid arthritis treatment method, article of manufacture, method of inhibiting the progression of joint structural damage, pharmaceutical composition, juvenile idiopathic arthritis (jia) treatment method and treatment method giant cell arteritis (gca)

• 收藏
• 分享

专利权人:

F. HOFFMANN-LA ROCHE AG;CHUGAI SEIYAKU KABUSHIKI KAISHA;GENENTECH INC

发明人:

ANGELIKA M. JAHREIS,JOHANNES F. SCHMIDT,KIMIO TERAO,MIN BAO,OLIVIER ALFRED HARARI,XIAOPING ZHANG

申请号：

BR112013011305

公开号：

BR112013011305A2

申请日:

2011.11.07

申请国别(地区):

BR

年份:

2017

代理人:

摘要：

The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/